Search

Your search keyword '"Boninsegna, S"' showing total 7 results
Start Over Author "Boninsegna, S" Publisher country:us
7 results on '"Boninsegna, S"'

1. Evolving clinical landscape of chronic hepatitis B: A multicenter Italian study

Author

Stroffolini, T, Almasio, P, Sagnelli, E, Mele, A, Gaeta, G, Andreone, P, Scuteri, A, Antonucci, G, Iacomi, F, Babudieri, S, Pintus, A, Stornaiuolo, G, Brancaccio, G, Brunetto, M, Sasso, R, Caporaso, N, Morisco, F, Chiaramonte, M, Lattanzi, E, Di Marco, V, Venezia, G, Fagiuoli, S, Boninsegna, S, Fattovich, G, Olivari, N, Ferrari, C, Giuberti, T, Ferrigno, L, Magnani, G, Massari, M, Mangano, C, Caserta, C, Messina, V, Pastore, G, Palattella, S, Piccinino, F, Stanzione, M, Pinzello, G, Vinci, M, Raimondo, G, Caccamo, G, Roffi, L, Bellia, V, Rizzetto, M, Smedile, A, Ciancio, A, Stroffolini T, Almasio PL, Sagnelli E, Mele A, Gaeta GB, Andreone P, Scuteri A, Antonucci G, Iacomi F, Babudieri S, Pintus A, Stornaiuolo G, Brancaccio G, Brunetto M, Sasso R, Caporaso N, Morisco F, Chiaramonte M, Lattanzi E, Di Marco V, Venezia G, Fagiuoli S, Boninsegna S, Fattovich G, Olivari N, Ferrari C, Giuberti T, Ferrigno L, Magnani G, Massari M, Mangano C, Caserta C, Messina V, Pastore G, Palattella S, Piccinino F, Stanzione M, Pinzello G, Vinci M, Raimondo G, Caccamo G, Roffi L, Bellia V, Rizzetto M, Smedile A, Ciancio A. Italian Hospitals' Collaborating Group., Stroffolini, T, Almasio, P, Sagnelli, E, Mele, A, Gaeta, G, Andreone, P, Scuteri, A, Antonucci, G, Iacomi, F, Babudieri, S, Pintus, A, Stornaiuolo, G, Brancaccio, G, Brunetto, M, Sasso, R, Caporaso, N, Morisco, F, Chiaramonte, M, Lattanzi, E, Di Marco, V, Venezia, G, Fagiuoli, S, Boninsegna, S, Fattovich, G, Olivari, N, Ferrari, C, Giuberti, T, Ferrigno, L, Magnani, G, Massari, M, Mangano, C, Caserta, C, Messina, V, Pastore, G, Palattella, S, Piccinino, F, Stanzione, M, Pinzello, G, Vinci, M, Raimondo, G, Caccamo, G, Roffi, L, Bellia, V, Rizzetto, M, Smedile, A, Ciancio, A, Stroffolini T, Almasio PL, Sagnelli E, Mele A, Gaeta GB, Andreone P, Scuteri A, Antonucci G, Iacomi F, Babudieri S, Pintus A, Stornaiuolo G, Brancaccio G, Brunetto M, Sasso R, Caporaso N, Morisco F, Chiaramonte M, Lattanzi E, Di Marco V, Venezia G, Fagiuoli S, Boninsegna S, Fattovich G, Olivari N, Ferrari C, Giuberti T, Ferrigno L, Magnani G, Massari M, Mangano C, Caserta C, Messina V, Pastore G, Palattella S, Piccinino F, Stanzione M, Pinzello G, Vinci M, Raimondo G, Caccamo G, Roffi L, Bellia V, Rizzetto M, Smedile A, and Ciancio A. Italian Hospitals' Collaborating Group.

Abstract

The aim of the study was to evaluate the characteristics of chronic hepatitis B with special reference to the geographical origin of the patients and to the prevalence of HBeAg and viral and non-viral co-factors of liver disease. A cross-sectional multicenter survey was undertaken, which enrolled 1,386 HBsAg chronic carriers observed consecutively in 21 referral centers over a 6-month period. The prevalence of HBeAg in patients was 11%; the presence of HBeAg was associated independently with a younger age and co-infection with HIV. Anti-HDV, anti-HCV, or anti-HIV antibodies were detected in 8.1%, 6.5%, and 2%, respectively. However, among the patients first diagnosed during the study period (incident cases), 14.3% were anti-HDV positive. Seven percent of the patients were immigrants; they were younger than Italian patients and 18% were HBeAg positive; no difference was observed in the prevalence of anti-HDV, anti-HCV, or anti-HIV antibodies. The presence of cirrhosis was associated independently with an age >52 years, the presence of anti-HDV or anti-HCV, alcohol use >4 drinks/day, and a high BMI. The clinical epidemiology of chronic hepatitis B virus (HBV) infection shows a dynamic profile, with the potential for re-emergence of cases with HBeAg or anti-HDV and an emerging impact of metabolic factors on the evolution of liver disease.

Published
2009

2. Serum ferritin as a predictor of treatment outcome in patients with chronic hepatitis C.

Author

Ferrara, F, Ventura, P, Vegetti, A, Guido, M, Abbati, G, Corradini, E, Fattovich, G, Ferrari, C, Tagliazucchi, M, Carbonieri, A, Orlandini, A, Fagiuoli, S, Boninsegna, S, Minola, E, Rizzo, G, Belussi, F, Felder, M, Massari, M, Pozzato, G, Bonetto, S, Rovere, P, Sardini, C, Borghi, A, Zeneroli, M, Toniutto, P, Rossi, E, Pietrangelo, A, Ferrara F, Ventura P, Vegetti A, Guido M, Abbati G, Corradini E, Fattovich G, Ferrari C, Tagliazucchi M, Carbonieri A, Orlandini A, Fagiuoli S, Boninsegna S, Minola E, Rizzo G, Belussi F, Felder M, Massari M, Pozzato G, Bonetto S, Rovere P, Sardini C, Borghi A, Zeneroli ML, Toniutto P, Rossi E, Pietrangelo A., Ferrara, F, Ventura, P, Vegetti, A, Guido, M, Abbati, G, Corradini, E, Fattovich, G, Ferrari, C, Tagliazucchi, M, Carbonieri, A, Orlandini, A, Fagiuoli, S, Boninsegna, S, Minola, E, Rizzo, G, Belussi, F, Felder, M, Massari, M, Pozzato, G, Bonetto, S, Rovere, P, Sardini, C, Borghi, A, Zeneroli, M, Toniutto, P, Rossi, E, Pietrangelo, A, Ferrara F, Ventura P, Vegetti A, Guido M, Abbati G, Corradini E, Fattovich G, Ferrari C, Tagliazucchi M, Carbonieri A, Orlandini A, Fagiuoli S, Boninsegna S, Minola E, Rizzo G, Belussi F, Felder M, Massari M, Pozzato G, Bonetto S, Rovere P, Sardini C, Borghi A, Zeneroli ML, Toniutto P, Rossi E, and Pietrangelo A.

Abstract

OBJECTIVES: Antiviral treatment in chronic hepatitis C (CHC) involves ribavirin, a hemolytic agent. We planned a prospective study to evaluate whether drug-induced iron perturbation is clinically relevant as it relates to therapeutic outcome. METHODS: Iron variables were sequentially assessed in 206 CHC patients undergoing antiviral therapy and were correlated with pretreatment iron status and histology, hemolysis, and therapeutic outcome. RESULTS: At week 1 of therapy, serum iron (SI), transferrin saturation (TS), and serum ferritin (SF) increased markedly in all patients. All iron parameters correlated with hemolysis up to week 4; this correlation was lost for SF at later time points. SF rise during treatment was inversely related to baseline SF and iron deposits in hepatic mesenchymal/Kupffer cells. Both baseline SF and mesenchymal iron significantly correlated with fibrosis at multivariate analysis (P=0.015 and 0.008, respectively). Interestingly, baseline SF, despite good specificity (89%), had low sensitivity in predicting siderosis (25%). During therapy, SI, TS, and hemolysis parameters did not correlate with sustained virological response (SVR), whereas SF rise became an independent predictor of therapeutic response: a 2.5-fold increase of SF at week 12 associated with higher likelihood of SVR (odds ratio 1.91, P=0.032). Accordingly, lack of mesenchymal iron deposits at the baseline biopsy correlated with SVR (odds ratio 3.02, P=0.043). CONCLUSIONS: In CHC, SF is a useful marker for assessing disease duration and progression before starting treatment and for predicting therapeutic response while on therapy. SF rise during antiviral therapy is largely independent of hemolysis and likely indicates activation of macrophages in response to antivirals.

Published
2009

3. THE BENEFIT OF ANTIVIRAL THERAPY ON FIBROSIS PROGRESSION DUE TO HCV RECURRENCE AFTER LIVER TRANSPLANTATION (LT): AN ITALIAN MULTICENTER STUDY

Author

De Martin, E, Senzolo, M, Ponziani, F, Vigano, R, Belli, L, Pinzello, G, Colledan, M, Donato, M, Di Paolo, D, Angelico, M, Rendina, M, Pompili, M, Merli, M, Villa, E, Russo, F, Boninsegna, S, Cillo, U, Gasbarrini, A, Toniutto, P, Fagiuoli, S, Burra, P, De Martin E, Senzolo M, Ponziani F, Vigano R, Belli LS, Pinzello G, Colledan M, Donato MF, Di Paolo D, Angelico M, Rendina M, Pompili M, Merli M, Villa E, Russo FP, Boninsegna S, Cillo U, Gasbarrini A, Toniutto P, Fagiuoli S, Burra P, De Martin, E, Senzolo, M, Ponziani, F, Vigano, R, Belli, L, Pinzello, G, Colledan, M, Donato, M, Di Paolo, D, Angelico, M, Rendina, M, Pompili, M, Merli, M, Villa, E, Russo, F, Boninsegna, S, Cillo, U, Gasbarrini, A, Toniutto, P, Fagiuoli, S, Burra, P, De Martin E, Senzolo M, Ponziani F, Vigano R, Belli LS, Pinzello G, Colledan M, Donato MF, Di Paolo D, Angelico M, Rendina M, Pompili M, Merli M, Villa E, Russo FP, Boninsegna S, Cillo U, Gasbarrini A, Toniutto P, Fagiuoli S, and Burra P

Published
2009

4. GENOTYPE 2 AND 3 RECURRENT HEPATITIS C AFTER LIVER TRANSPLANTATION: EXCELLENT RESULTS WITH SUBOPTIMAL DOSES OF ANTIVIRAL THERAPY

Author

Ponziani, F, Vigano, R, Belli, L, Pinzello, G, Colledan, M, De Martin, E, Burra, P, Boninsegna, S, Donato, F, Di Paolo, D, Angelico, M, Rendina, M, Pompili, M, Gasbarrini, A, Fagiuoli, S, Ponziani FR, Vigano R, Belli L, Pinzello G, Colledan M, De Martin E, Burra P, Boninsegna S, Donato F, Di Paolo D, Angelico M, Rendina M, Pompili M, Gasbarrini A, Fagiuoli S, Ponziani, F, Vigano, R, Belli, L, Pinzello, G, Colledan, M, De Martin, E, Burra, P, Boninsegna, S, Donato, F, Di Paolo, D, Angelico, M, Rendina, M, Pompili, M, Gasbarrini, A, Fagiuoli, S, Ponziani FR, Vigano R, Belli L, Pinzello G, Colledan M, De Martin E, Burra P, Boninsegna S, Donato F, Di Paolo D, Angelico M, Rendina M, Pompili M, Gasbarrini A, and Fagiuoli S

Published
2009

5. FIBROSIS PROGRESSION AFTER ANTIVIRAL TREATMENT (AT) FOR HCV RECURRENCE FOLLOWING LIVER TRANSPLANTATION

Author

De Martin, E, Masier, A, Senzolo, M, Boninsegna, S, Ponziani, F, Vigano, R, Belli, L, Pinzello, G, Colledan, M, Donato, F, Di Paolo, D, Angelico, M, Rendina, M, Pompili, M, Gasbarrini, A, Russo, F, Cillo, U, Fagiuoli, S, Burra, P, De Martin E, Masier A, Senzolo M, Boninsegna S, Ponziani FR, Vigano R, Belli L, Pinzello G, Colledan M, Donato FC, Di Paolo D, Angelico M, Rendina M, Pompili M, Gasbarrini A, Russo FP, Cillo U, Fagiuoli S, Burra P, De Martin, E, Masier, A, Senzolo, M, Boninsegna, S, Ponziani, F, Vigano, R, Belli, L, Pinzello, G, Colledan, M, Donato, F, Di Paolo, D, Angelico, M, Rendina, M, Pompili, M, Gasbarrini, A, Russo, F, Cillo, U, Fagiuoli, S, Burra, P, De Martin E, Masier A, Senzolo M, Boninsegna S, Ponziani FR, Vigano R, Belli L, Pinzello G, Colledan M, Donato FC, Di Paolo D, Angelico M, Rendina M, Pompili M, Gasbarrini A, Russo FP, Cillo U, Fagiuoli S, and Burra P

Published
2009

6. Liver transplantation for HCV cirrhosis: Improved survival in recent years and increased severity of recurrent disease in female recipients: Results of a long term retrospective study

Author

Belli, L, Burroughs, A, Burra, P, Alberti, A, Samonakis, D, Cammà, C, De Carlis, L, Minola, E, Quaglia, A, Zavaglia, C, Vangeli, M, Patch, D, Dhillon, A, Cillo, U, Guido, M, Fagiuoli, S, Giacomoni, A, Slim, O, Airoldi, A, Boninsegna, S, Davidson, B, Rolles, K, Pinzello, G, Belli, Luca S., Burroughs, Andrew K., Burra, Patrizia, Alberti, Alberto B., Samonakis, Dimitrios, Cammà, Calogero, De Carlis, Luciano, Minola, Ernesto, Quaglia, Alberto, Zavaglia, Claudio, Vangeli, Marcello, Patch, David, Dhillon, Amar, Cillo, Umberto, Guido, Maria, Fagiuoli, Stefano, Giacomoni, Alessandro, Slim, Omar A., Airoldi, Aldo, Boninsegna, Sara, Davidson, Brian R., Rolles, Keith, Pinzello, Giovambattista, Belli, L, Burroughs, A, Burra, P, Alberti, A, Samonakis, D, Cammà, C, De Carlis, L, Minola, E, Quaglia, A, Zavaglia, C, Vangeli, M, Patch, D, Dhillon, A, Cillo, U, Guido, M, Fagiuoli, S, Giacomoni, A, Slim, O, Airoldi, A, Boninsegna, S, Davidson, B, Rolles, K, Pinzello, G, Belli, Luca S., Burroughs, Andrew K., Burra, Patrizia, Alberti, Alberto B., Samonakis, Dimitrios, Cammà, Calogero, De Carlis, Luciano, Minola, Ernesto, Quaglia, Alberto, Zavaglia, Claudio, Vangeli, Marcello, Patch, David, Dhillon, Amar, Cillo, Umberto, Guido, Maria, Fagiuoli, Stefano, Giacomoni, Alessandro, Slim, Omar A., Airoldi, Aldo, Boninsegna, Sara, Davidson, Brian R., Rolles, Keith, and Pinzello, Giovambattista

Abstract

In recent years, a worsening outcome of hepatitis C virus (HCV)-positive recipients and a faster progression of recurrent disease to overt cirrhosis have been reported. Our aims were to 1) assess patient survival and development of severe recurrent disease (Ishak fibrosis score > 3) in different transplant years; and 2) model the effects of pre- and post-liver transplantation (LT) variables on the severity of recurrent disease. A multicenter retrospective analysis was conducted on 502 consecutive HCV-positive transplant recipients between January 1990 and December 2002. Protocol liver biopsies were obtained at 1, 3, 5, 7, and 10 yr post-LT ir almost 90% of the patients. All 502 patients were included in the overall survival analysis, while only the 354 patients with a follow-up longer than 1 yr were considered for the analysis of predictors of disease progression. The overall Kaplan-Meier survival rates were 78.7%, 66.3%, and 58.6%, at 12, 60, and 120 months, respectively, and a trend for a better patient survival over the years emerged from all 3 centers. The cumulative probability of developing HCV-related recurrent severe fibrosis (Ishak score 4-6) in the cohort of 354 patients who survived at least 1 yr remained unchanged over the years. Multivariate analysis indicated that older donors (P = 0.0001) and female gender of recipient (P = 0.02) were the 2 major risk factors for the development of severe recurrent disease, while the adoption of antilymphocytic preparations was associated with a less aggressive course (P = 0.03). Two of these prognostic factors, donor age and recipient gender, are easily available before LT and their combination showed an important synergy, such that a female recipient not only had a much higher probability of severe recurrent disease than a male recipient but her risk increased with the increasing age of the donor, reaching almost 100% when the age of the donor was 60 or older. In conclusion, a trend for a better patient survival

Published
2007

7. HLA-DRB1 donor-recipient mismatch affects the outcome of hepatitis C disease recurrence after liver transplantation

Author

Belli, L, Burra, P, Poli, F, Alberti, A, Silini, E, Zavaglia, C, Fagiuoli, S, Prando, D, Espadas De Arias, A, Boninsegna, S, Tinelli, C, Scalamogna, M, De Carlis, L, Pinzello, G, Belli, Luca Saverio, Burra, Patrizia, Poli, Francesca, Alberti, Alberto Battista, Silini, Enrico, Zavaglia, Claudio, Fagiuoli, Stefano, Prando, Daniela, Espadas De Arias, Alejandro, Boninsegna, Sara, Tinelli, Carmine, Scalamogna, Mario, De Carlis, Luciano, Pinzello, Giovambattista, Belli, L, Burra, P, Poli, F, Alberti, A, Silini, E, Zavaglia, C, Fagiuoli, S, Prando, D, Espadas De Arias, A, Boninsegna, S, Tinelli, C, Scalamogna, M, De Carlis, L, Pinzello, G, Belli, Luca Saverio, Burra, Patrizia, Poli, Francesca, Alberti, Alberto Battista, Silini, Enrico, Zavaglia, Claudio, Fagiuoli, Stefano, Prando, Daniela, Espadas De Arias, Alejandro, Boninsegna, Sara, Tinelli, Carmine, Scalamogna, Mario, De Carlis, Luciano, and Pinzello, Giovambattista

Abstract

Background & Aims: This study extends our previously reported observations that various immunological factors are associated with the occurrence of histologically proven recurrent hepatitis C. The two specific issues investigated were to confirm the associations of MHC alleles and donor/recipient mismatch with the occurrence of recurrent hepatitis C in an independent cohort of newly transplanted patients and to look for immunologic and nonimmunologic variables affecting the severity of the recurrent disease. Methods: Two separate cohorts of consecutive patients were studied: a look-back cohort (LC) of 120 patients and a cohort for studying the disease progression (CSDP) of 190 patients. Protocol liver biopsies were obtained at least 1, 3, 5, 7, and 10 years after liver transplantation (LT). Results: A fully mismatched donor/recipient pair at the DRB1 locus was confirmed to be associated with both the recurrence of histologic hepatitis in the LC (59% vs 23%, P = .0002) and its progression beyond stage 3 in the CSPD (71.4% vs 39.3%, P = .0003). Relevant immunologic and nonimmunologic variables were included into a multivariate Cox proportional model and three variables, namely, donor age, full HLA-DRB1 donor-recipient mismatch, and HLA B14, resulted in independent risk factors for the development of severe fibrosis. Conclusion: This study provides evidence that DRB1 donor-recipient mismatch affects both the occurrence and progression of recurrent hepatitis C disease. This information is clinically relevant as it may help to better allocate organs and to recognize patients at risk for progression so that specific interventions can be implemented. © 2006 by the American Gastroenterological Association Institute

Published
2006

Catalog

Books, media, physical & digital resources
See catalog results